2g48: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,329,557 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,329,557 edits
No edit summary
Line 1: Line 1:
[[Image:2g48.jpg|left|200px]]
{{Seed}}
[[Image:2g48.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2g48|  PDB=2g48  |  SCENE=  }}  
{{STRUCTURE_2g48|  PDB=2g48  |  SCENE=  }}  


'''crystal structure of human insulin-degrading enzyme in complex with amylin'''
===crystal structure of human insulin-degrading enzyme in complex with amylin===




==Overview==
<!--  
Insulin-degrading enzyme (IDE), a Zn2+-metalloprotease, is involved in the clearance of insulin and amyloid-beta (refs 1-3). Loss-of-function mutations of IDE in rodents cause glucose intolerance and cerebral accumulation of amyloid-beta, whereas enhanced IDE activity effectively reduces brain amyloid-beta (refs 4-7). Here we report structures of human IDE in complex with four substrates (insulin B chain, amyloid-beta peptide (1-40), amylin and glucagon). The amino- and carboxy-terminal domains of IDE (IDE-N and IDE-C, respectively) form an enclosed cage just large enough to encapsulate insulin. Extensive contacts between IDE-N and IDE-C keep the degradation chamber of IDE inaccessible to substrates. Repositioning of the IDE domains enables substrate access to the catalytic cavity. IDE uses size and charge distribution of the substrate-binding cavity selectively to entrap structurally diverse polypeptides. The enclosed substrate undergoes conformational changes to form beta-sheets with two discrete regions of IDE for its degradation. Consistent with this model, mutations disrupting the contacts between IDE-N and IDE-C increase IDE catalytic activity 40-fold. The molecular basis for substrate recognition and allosteric regulation of IDE could aid in designing IDE-based therapies to control cerebral amyloid-beta and blood sugar concentrations.
The line below this paragraph, {{ABSTRACT_PUBMED_17051221}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 17051221 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_17051221}}


==About this Structure==
==About this Structure==
Line 26: Line 30:
[[Category: Tang, W J.]]
[[Category: Tang, W J.]]
[[Category: Protein-peptide complex]]
[[Category: Protein-peptide complex]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 04:40:26 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 02:20:51 2008''

Revision as of 23:20, 27 July 2008

File:2g48.png

Template:STRUCTURE 2g48

crystal structure of human insulin-degrading enzyme in complex with amylin

Template:ABSTRACT PUBMED 17051221

About this Structure

2G48 is a Protein complex structure of sequences from Homo sapiens. Full crystallographic information is available from OCA.

Reference

Structures of human insulin-degrading enzyme reveal a new substrate recognition mechanism., Shen Y, Joachimiak A, Rosner MR, Tang WJ, Nature. 2006 Oct 19;443(7113):870-4. Epub 2006 Oct 11. PMID:17051221

Page seeded by OCA on Mon Jul 28 02:20:51 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=2g48&oldid=676405"